77 varieties withdraw from the net!

On April 1, the Shanxi Provincial Pharmaceutical Equipment Centralized Bidding Procurement Network issued the "Notice on Publicizing Some Enterprises' Revocation of the Platform for Online Purchase Qualifications".
The notice shows that a total of 77 varieties have been withdrawn from the network, involving 42 domestic and foreign pharmaceutical companies, including CSK, Novartis, Qilu and others
.
Judging from the list, the 77 varieties of the application for withdrawal from the network include not only commonly used clinical drugs, but also some heavy tumor drug varieties
.
For example, the omeprazole enteric-coated capsules of Cucurbita Pharmaceutical Co.
, Ltd.
applied for withdrawal from the website in Shanxi Province.
This product is a proton pump inhibitor commonly used in clinical treatment of gastritis, and is a category A variety of the National Medical Insurance Drug List (2021 Edition).
, and was included in the National Essential Medicines List (2018 edition)
.
According to the terminal data of Minet.
com, the domestic terminal sales of omeprazole oral preparations will be 3.
37 billion yuan in 2020, of which the terminal sales of Jinhua Kangenbei omeprazole enteric-coated capsules will be 550 million yuan, accounting for 16.
3% of the market share
.
Oncology drugs that have applied for withdrawal from the network in Shanxi Province, such as CSK's lapatinib tosylate tablets (Tailisha), which is mainly used to treat breast cancer, entered the Chinese market in 2013 and achieved global sales of US$4 million However, with the end of the patent period, the influx of generic drugs from many companies including Hengrui and Kelun has brought an impact on the performance of the original research products
.
Another example is Qilu Pharmaceutical's four specifications of Sigio tablets, which is an anti-gastric cancer drug.
In March 2019, Qilu Pharmaceutical's product became the first domestically reviewed product of the same variety
.
According to the data of Minet.
com, in recent years, the sales of Tigio terminals in Chinese public medical institutions have increased year by year.
In 2017, the sales were 4.
52 billion yuan, of which capsules accounted for more than 98% of the market share
.
From the perspective of the competition pattern, Shandong New Times Pharmaceutical occupies half of the market share, followed by Qilu and Hengrui, accounting for 11.
72% and 17.
14% of the market respectively
.
In the second round of centralized procurement, Hengrui and Qilu were the winning bidders for Teggio products, of which Hengrui’s price of 67.
95 yuan (20mg, 12 capsules) was lower than that of Qilu
.
New Era Pharmaceuticals is not listed as a candidate for centralized procurement because it has not been reviewed.

.
Under the normalization of centralized procurement, drug prices have become a trend, coupled with the continuous rise of raw materials and costs, both domestic and foreign pharmaceutical companies will inevitably be affected, and many companies have to reluctantly abandon bidding, withdraw from the network, or even stop production
.
In addition to Shanxi Province, since this year, many provinces have issued notices to withdraw related products from the Internet
.
For example, on March 17, the Jiangsu Provincial Public Resource Trading Platform issued a notice to cancel the listing of drugs that had no acceptance record on the platform for one year or more as of March 15, 2022
.
According to the drug serial number, a total of 6,076 drugs were withdrawn from the network, involving many large domestic enterprises such as Kelun, Yangzijiang, CSPC, Livzon and Qilu
.
Earlier on March 4, the Jiangsu Provincial Public Resource Trading Center also issued a notice to cancel the listing of drugs.
The notice showed that 35 drugs such as Liganlong Granules and Shuanghuanglian Oral Liquid were to be withdrawn from the listing
.
And all enterprises voluntarily apply for withdrawal from the network
.
In mid-February, the Shaanxi Provincial Public Resources Trading Center issued a notice on the cancellation of the eligibility of some products to be listed on the Internet, involving the withdrawal of 9 products including Yanhuning for injection, lipoic acid injection, famotidine for injection, and nadroparin calcium for injection.
8 pharmaceutical companies, including Chongqing Yaoyou Pharmaceutical, Sichuan Meida Kanghuakang Pharmaceutical, and Hainan Sanye Pharmaceutical, have been disqualified from being listed on the Internet
.
From the perspective of the industry, with the withdrawal of drugs from the Internet becoming the norm, the market reshuffle is also intensifying.
In order to win more initiative in the market, pharmaceutical companies need to pay attention to the research and development of innovative drug products, develop competitive products with core competitiveness, and Strictly control the quality of drugs, and actively do a good job in consistency evaluation
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.